The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

The LIDERA trial's early, robust success with the oral SERD giredestrant in adjuvant therapy is surprising. In the metastatic setting, these drugs primarily benefit tumors with ESR1 mutations, which are acquired after therapy and rare at diagnosis. This paradoxical result suggests a different mechanism of action in early-stage disease and necessitates longer follow-up to confirm the finding.

Ladera showed a significant benefit for geridesterant over standard endocrine therapy in early breast cancer with an efficacy signal similar to initial readouts for CDK4/6 inhibitors. Since CDK4/6 inhibitors were excluded, this creates a clinical debate: are these treatments interchangeable, sequential, or for different populations?

The failure of Roche's gerodestrant when combined with a CDK4/6 inhibitor suggests these oral SERDs may not add benefit to that backbone. This contrasts with its success alone in an adjuvant setting, reframing the drugs as an "either-or" choice rather than a combination therapy in the first-line setting.

In the EMBER-3 trial, the combination of the oral SERD imlunestrant and the CDK4/6 inhibitor abemaciclib showed a 41% reduction in progression risk versus the SERD alone. Critically, this benefit was observed regardless of the patient's ESR1 mutation status, indicating a broader mechanism of action.

The failure of the PERSEVERA trial, which tested a similar drug in an unselected patient population, highlights the critical importance of SERENA-6's biomarker-driven approach. It proves that targeting only patients with the ESR1 mutation is necessary for efficacy, reinforcing the core value of precision oncology.

The LDERA trial showed early, significant benefit for adjuvant gerodestrant, an oral SERD. This positive result creates a clinical challenge: how to position this new agent relative to adjuvant abemaciclib, which has a proven overall survival benefit in high-risk patients but was not studied in combination with a SERD.

While the LADERA study showed a benefit for oral SERD gerodestrant over standard endocrine therapy, its applicability is questionable. In the metastatic setting, adding an oral SERD to a CDK inhibitor did not show a statistically significant benefit over an AI plus CDK, raising doubts about its added value in the adjuvant CDK era.

The success of oral SERD clinical trials hinges on study design. Trials like AMIRA-3 and Axilera failed in their overall populations but showed benefit in ESR1-mutant subgroups. EMERALD succeeded by making this subgroup a co-primary endpoint, proving the importance of targeting the right population from the outset.